BBIO
BridgeBio Pharma, Inc.
Set alert
74.95 USD +4.22 +5.97%
71.91 Day range 75.65
61.37 52-week range 90.17
- YTD
- -2.01%
- 1 year
- +18.27%
- Open
- 72.85
- Prev close
- 70.73
- Mkt cap
- 14.65B
- Vol
- 5.77M
- Avg vol
- 2.52M
- EPS
- -3.56
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 71.91
- High
- 75.65
- Forward P/E
- -333.67
- Beta
- 0.97
- Short ratio
- 6.50
- Inst. own
- 99.55%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 23, 2027
- 50-d avg
- 70.43
- 200-d avg
- 72.76
- 1y target
- 107.81
Financial health
Altman Z-Score
-0.09 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C-1 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 1
Valuation
P/E -20.2×
FY 2017 5y median -9.5× FY 2025
P/S 30.0×
FY 2017 5y median 30.0× FY 2025
P/B -7.3×
FY 2017 5y median -3.5× FY 2025
P/FCF -33.8×
FY 2017 5y median -9.8× FY 2025
EV/EBITDA -25.5×
FY 2017 5y median -14.0× FY 2025
EV/Sales 34.3×
FY 2017 5y median 34.3× FY 2025
FCF Yield -3.0%
FY 2017 5y median -10.2% FY 2025
Profitability
Gross Margin 94.4%
FY 2017 5y median 95.5% FY 2025
Operating Margin -113.3%
FY 2017 5y median -659.6% FY 2025
Net Margin -145.3%
FY 2017 5y median -619.7% FY 2025
ROE 35.1%
FY 2017 5y median 38.4% FY 2025
ROIC -108.5%
FY 2017 5y median -101.4% FY 2025
ROA -77.9%
FY 2017 5y median -77.2% FY 2025
Growth (YoY)
Revenue 126.3%
FY 2017 FY 2025
Operating Income 4.0%
FY 2017 FY 2025
EPS (diluted) -31.6%
FY 2017 FY 2025
Free Cash Flow 14.3%
FY 2017 FY 2025
Financial Health
Current Ratio 2.6×
FY 2017 5y median 4.5× FY 2025
Quick Ratio 2.5×
FY 2017 5y median 4.5× FY 2025
Debt / Equity -1.3×
FY 2017 5y median -1.3× FY 2025
Net Debt / EBITDA -3.2×
FY 2017 5y median -2.5× FY 2025
Interest Coverage -10.7×
FY 2017 5y median -7.5× FY 2025
Dividends
Dividend Yield 0.0%
FY 2017 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2017 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31